{"doi":"10.1056/nejmoa1606774","title":"Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer","abstract":"<h4>Background</h4>Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).<h4>Methods</h4>In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety.<h4>Results</h4>Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%).<h4>Conclusions</h4>In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).","journal":"New England Journal of Medicine","year":2016,"id":11537,"datarank":16.881548620318675,"base_score":9.20833836930551,"endowment":9.20833836930551,"self_citation_contribution":1.3812507553958266,"citation_network_contribution":15.500297864922848,"self_endowment_contribution":1.3812507553958266,"citer_contribution":15.500297864922848,"corpus_percentile":93.5,"corpus_rank":1064,"citation_count":9979,"citer_count":167,"citers_with_citation_signal":167,"citers_with_endowment":167,"datacite_reuse_total":0,"is_dataset":false,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2016-11-10","authors":[{"id":33754,"name":"Delvys Rodríguez-Abreu","orcid":null,"position":1,"is_corresponding":false},{"id":92206,"name":"Andrew G. Robinson","orcid":null,"position":2,"is_corresponding":false},{"id":33767,"name":"Rina Hui","orcid":"0000-0003-0696-7442","position":3,"is_corresponding":false},{"id":92207,"name":"Tibor Csőszi","orcid":"0000-0002-7742-1968","position":4,"is_corresponding":false},{"id":92208,"name":"Andrea Fülöp","orcid":null,"position":5,"is_corresponding":false},{"id":92209,"name":"Maya Gottfried","orcid":null,"position":6,"is_corresponding":false},{"id":33764,"name":"Nir Peled","orcid":"0000-0003-3714-4377","position":7,"is_corresponding":false},{"id":92210,"name":"Ali Tafreshi","orcid":"0000-0002-8956-3373","position":8,"is_corresponding":false},{"id":92211,"name":"Sinead Cuffe","orcid":null,"position":9,"is_corresponding":false},{"id":92212,"name":"Mary O’Brien","orcid":"0000-0002-8557-8957","position":10,"is_corresponding":false},{"id":92213,"name":"Suman Rao","orcid":null,"position":11,"is_corresponding":false},{"id":92214,"name":"Katsuyuki Hotta","orcid":"0000-0002-0112-0843","position":12,"is_corresponding":false},{"id":92215,"name":"Melanie A. Leiby","orcid":null,"position":13,"is_corresponding":false},{"id":65226,"name":"Gregory M. Lubiniecki","orcid":null,"position":14,"is_corresponding":false},{"id":65227,"name":"Yue Shentu","orcid":"0000-0002-9547-1387","position":15,"is_corresponding":false},{"id":92216,"name":"Reshma Rangwala","orcid":null,"position":16,"is_corresponding":false},{"id":1563,"name":"Julie R. Brahmer","orcid":"0000-0002-2443-8395","position":17,"is_corresponding":false},{"id":33778,"name":"Delvys Rodríguez‐Abreu","orcid":"0000-0003-0506-1366","position":18,"is_corresponding":false},{"id":92217,"name":"Andrew Robinson","orcid":"0000-0003-1152-4275","position":19,"is_corresponding":false},{"id":92218,"name":"Sinéad Cuffe","orcid":null,"position":20,"is_corresponding":false},{"id":23851,"name":"Martin Reck","orcid":"0000-0002-5348-4462","position":0,"is_corresponding":true}],"reference_count":14,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-03-01T18:20:47.508186Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}